Announcement of providing guarantee for the holding company
Release time:
2021-05-20
证券简称:尖峰集团 证券代码:600668 编号:临2020-006
浙江尖峰集团股份有限公司
为控股子公司提供担保的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示
● 被担保人名称:浙江尖峰药业有限公司、上海北卡医药技术有限公司及其全资子公司、贵州黄平尖峰水泥有限公司、浙江尖峰国际贸易有限公司。
● 拟设定融资担保额度:设定融资担保额度8.8亿元。
● 本次担保是否有反担保:无
● 对外担保逾期的累计数量:无
一、担保情况概述
2020年4月24日,公司以现场与通讯表决相结合的方式召开了第十届董事会第14次会议,公司现有八名董事,全体董事亲自参加了会议,符合《公司法》和《公司章程》的有关规定,所做决议合法有效。会议由蒋晓萌董事长主持,经审议与表决,以8票同意、0票反对、0票弃权,审议通过了《关于对控股子公司提供担保的议案》。
该议案需提交股东大会审议。
二、被担保人基本情况
1、浙江尖峰药业有限公司(以下简称“尖峰药业”),注册资本29853万元,其中:本公司占99.16%,注册地址:浙江金华市婺城区白汤下线高畈段58号X02幢办公质检楼二楼,主要经营:药品研发与生产(凭有效许可证件经营);进口生产、科研所需的原辅料;进口机械设备、仪器仪表及零配件。
2、上海北卡医药技术有限公司(以下简称“上海北卡”),注册资本2275.93万元,其中:本公司占61.48%,注册地址:上海市松江区申港路3802号21幢,主要经营:医药和化学专业技术领域内的技术开发、技术咨询、技术服务、技术转让;机械设备、仪器仪表、食用农产品(不含生猪产品)、化肥、饲料添加剂、化工原料及产品(除危险品)批发零售;医药中间体的开发、销售;从事货物及技术的进出口业务。上海北卡拥有三家全资子公司:安徽新北卡化学有限公司、安徽尖峰北卡药业有限公司、安徽众望制药有限公司。
3、贵州黄平尖峰水泥有限公司(以下简称“贵州尖峰”),注册资本15000万元,本公司占100%,注册地址:贵州省黔东南苗族侗族自治州黄平县谷陇工业园区,主要经营:研发、生产、销售水泥制品及工艺设备;普通硅酸盐水泥及商品砼、水泥制品、石灰石、人工砂、碎石、骨料的制造销售。
4、浙江尖峰国际贸易有限公司(以下简称“尖峰国贸”),注册资本3000万元,其中:本公司占93.33%、尖峰药业占6.67%,注册地址:浙江金东经济开发区常春西路88号,主要经营: 国家法律法规允许的、无需前置审批的货物与技术进出口;道路货物运输;道路运输站(场)经营;食品经营;医药中间体、制药设备等销售及网上销售;国家法律和政策允许的商务咨询服务活动;开展进出口货物的国际运输代理业务,普通货物仓储服务。
三、上述子公司2019年经审计的主要财务数据(单位:万元)
|
|
总资产 |
负债总额 |
流动负债总额 |
银行借款总额 |
资产净额 |
营业总收入 |
归属于母公司所有者净利润 |
|
尖峰药业 |
152,583.62 |
94,668.43 |
89,358.62 |
200.00 |
57,915.19 |
158,023.23 |
2,246.16 |
|
上海北卡 |
32,909.43 |
20,637.00 |
20,445.93 |
|
12,272.43 |
30,701.87 |
-1,880.02 |
|
尖峰国贸 |
14,899.38 |
12,084.51 |
11,987.01 |
|
2,814.87 |
13,551.38 |
701.79 |
|
贵州尖峰 |
57,039.16 |
46,634.64 |
36,634.64 |
10,000.00 |
10,404.52 |
|
-1,166.62 |
四、提供担保的主要内容
1、对控股子公司的融资及担保,设定如下额度:
|
被担保单位 |
额度(万元) |
|
浙江尖峰药业有限公司 |
30000 |
|
上海北卡医药技术有限公司及其全资子公司 |
20000 |
|
贵州黄平尖峰水泥有限公司 |
30000 |
|
浙江尖峰国际贸易有限公司 |
8000 |
|
合计 |
88000 |
同意上海北卡根据实际经营情况与其下属各全资子公司共同使用上述额度。
2、尖峰国贸是大连商品交易所和郑州商品交易所的指定交割仓库,并且正在申请上海期货交易所的期货交割仓库资质,根据各交易所的要求,需要本公司提供保函,对尖峰国贸开展的期货交割仓库业务提供担保。另外,尖峰国贸从事经铁路运输的仓储物流业务,根据铁路部门相关规定,需要本公司提供保函,为尖峰国贸从铁路提货提供担保。
为了保障尖峰国贸顺利开展期货交割仓库和铁路仓储物流业务,拟同意为尖峰国贸的期货交割仓库业务及尖峰国贸从铁路提货出具保函,提供担保。
在设定额度内的金融机构借款及担保事宜均授权本公司董事长决定执行。
五、董事会意见
以上被担保公司都是本公司的控股子公司,本公司能有效控制担保风险,董事会同意以上的担保。
公司三名独立董事对该事项发表了独立意见,认为:被担保公司都是本公司的控股子公司,本公司能有效控制担保风险,该决议的形成符合《公司法》、《公司章程》等有关规定,没有损害中小股东的利益。同意为上述控股子公司提供担保。
六、累计对外担保数量及逾期担保的数量
截止本公告披露日,公司对外担保余额为11000万元,占公司2019年末经审计的合并归属于母公司所有者权益合计的2.90%,均为对控股子公司提供的担保。
截止本公告披露日,本公司没有逾期担保。
特此公告
浙江尖峰集团股份有限公司
董事会
二〇二〇年四月二十八日
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11